Pharmaceutical

Marksans Pharma Reports Q3FY26 with Revenue Growth and EBITDA Margin Expansion

● Feb 6, 2026

About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in...

Emcure Pharmaceuticals Q3 FY26 Earnings Results

● Feb 5, 2026

Executive Summary Emcure Pharmaceuticals Ltd reported Q3FY26 revenues of ₹2,363 crore, up 20.38% YoY, with consolidated net profit surging 48.08%...

Mankind Pharma Q3 FY26 Earnings Results

● Feb 3, 2026

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and...

Corona Q3 FY26 Earnings Results

● Feb 3, 2026

Executive Summary Corona Remedies Ltd reported Q3FY26 revenues of ₹342 crore, up 14.37% YoY, with consolidated net profit increasing 39.13%...

Sun Pharmaceutical Q3 FY26 Earnings Results

● Feb 2, 2026

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and...

Gland Pharma Q3 FY26 Earnings Results

● Jan 29, 2026

Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of ₹1,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32%...

Innova Captab Q3 FY26 Earnings Results

● Jan 28, 2026

Executive Summary Innova Captab Ltd reported Q3FY26 revenues of ₹450 crore, up 42.41% YoY, with consolidated net profit rising 23.53%...

RPG Life Sciences Q3 FY26 Earnings Results

● Jan 28, 2026

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Q3 FY26...

Alivus Life Sciences shares climb as third-quarter profit rises 9.7%

● Jan 22, 2026

Alivus Life Sciences Ltd (NSE: ALIVUS) shares increased by 1.36% to ₹873.00 on the National Stock Exchange on Thursday. The...

Jagsonpal Pharmaceuticals Q3 FY26 Results Show Stable Operations Amid Modest Growth

● Jan 22, 2026

Jagsonpal Pharmaceuticals Ltd on Thursday reported largely stable performance for the quarter ended December 31, 2025, with muted top-line movement...